Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Diluted Average) (2022 - 2025)

Silence Therapeutics (SLN) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 2.12% to $141.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.7 million through Dec 2025, up 2.12% year-over-year, with the annual reading at $141.7 million for FY2025, 2.12% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $141.7 million in Q4 2025 for Silence Therapeutics, roughly flat from $141.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $141.7 million in Q2 2025 to a low of $113.3 million in Q4 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $136.6 million across 4 years, with a median of $140.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 21.91% in 2023 and later rose 0.35% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $113.3 million in 2022, then increased by 21.91% to $138.1 million in 2023, then grew by 0.46% to $138.8 million in 2024, then grew by 2.12% to $141.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SLN at $141.7 million in Q4 2025, $141.7 million in Q3 2025, and $141.7 million in Q2 2025.